Author

S. Sinclair

OpenAlex ID: A5126200724

TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancer

2026 · I. Schlam, D. Trapani, et al. · ESMO Open · 1

Abstract PD7-02: Transcriptomic profiling of the tumor microenvironment indicates differential response to neoadjuvant chemotherapy with and without pembrolizumab in early TNBC

2026 · J. Gomez Tejeda Zanudo, S. Kirschner, et al. · Clinical Cancer Research · 1

Abstract PS3-11-04: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with HER2+ Breast Cancer - Results from the ATOP Study

2026 · R. A. Freedman, H. Heiling, et al. · Clinical Cancer Research · 1

34P AI-based assessment of tumor-infiltrating Lymphocytes (TILs) in metastatic triple-negative breast cancer (mTNBC) treated with carboplatin +/- nivolumab

2026 · I. Schlam, K. AbdulJabbar, et al. · ESMO Open

Abstract PS4-07-18: Association of tumor-infiltrating lymphocytes (TILs) with outcomes in patients with early TNBC treated with neoadjuvant chemotherapy with or without pembrolizumab

2026 · R. S. Lee, Q. Jin, et al. · Clinical Cancer Research

Abstract PD1-08: Trade: 6-month abemaciclib tolerability after initial dose escalation in early HR+/HER2- breast cancer

2026 · I. Schlam, D. Trapani, et al. · Clinical Cancer Research

Works count: 6

Citation count: 3

H-index: 1

I10-index: